

# A STUDY OF GARDASIL (V501) IN PREADOLESCENTS AND ADOLESCENTS (V501-018)

at <https://tinyurl.com/Gardasil-Clinical-Data>

SERIOUS ADVERSE EVENTS	PLACEBO IN BASE VACCINE PHASE AND FOLLOW-UP* # Events
<b>Blood and lymphatic system disorders</b> -- Haemorrhagic anaemia	0
<b>Gastrointestinal disorders</b> -- Colitis ulcerative	0
<b>General disorders</b> -- Chest pain	0
<b>Infections and infestations</b> -- Appendicitis -- Localised infection	0 0
<b>Injury, poisoning and procedural complications</b> -- Meniscus injury -- Road traffic accident	0 0
<b>Metabolism and nutrition disorders</b> -- Type 1 diabetes mellitus	0
<b>Musculoskeletal and connective tissue disorders</b> -- Pain in extremity	0
<b>Nervous system disorders</b> -- VIIth nerve paralysis -- Tonic clonic movements	0 0
<b>Renal and urinary disorders</b> -- Acute kidney injury	0
<b>Reproductive system and breast disorders</b> -- Dysfunctional uterine bleeding	0

\* Represents 584 participants who were randomized into the Placebo Group, who received three 0.5 mL intramuscular injections of placebo vaccine at Day 1, Month 2, and Month 6, and had safety follow-up. Adverse events are reported for this group from Day 1 to Month 30. See Stanley Plotkin Deposition of January 11, 2018. Video at [tinyurl.com/HPV-Placebo-Study](https://tinyurl.com/HPV-Placebo-Study); Transcript pages 197-202, at [tinyurl.com/Plotkin-Deposition-Transcript](https://tinyurl.com/Plotkin-Deposition-Transcript).

© PRBWorks